News

In an interview with Targeted Oncology, Chung-Han Lee, MD, PhD further discussed the results of the phase 2 trial of the combination of cabozantinib and nivolumab in patients with metastatic non-clear cell RCC and how it impacts the future of this space.

Pyrotinib combined with apecitabine demonstrated promising activity in patients with HER2-positive breast cancer that have brain metastases, according to findings from the prospective phase 2 PERMEATE study.

Oncologists at FCS, Lucio N. Gordan, MD and Ivor Percent, MD have published findings from the CheckMate 920 clinical trial.

Florida Cancer Specialists shares profile of Katy Phelan, PhD, the director of the organizations Genetics Laboratory.

A multivariate analysis of response rates of patients with metastatic renal cell carcinoma identified which factors are associated with a partial or complete response to first-line doublet immunotherapy or immunotherapy/tyrosine kinase inhibitor combinations.

Following positive early results from the ASPEN-01 clinical trial, the first patient with HER2-positve gastric or gastroesophageal cancer has received the experimental combination of evorpacept, trastuzumab, ramucirumab, and paclitaxel in ASPEN-06.

Significantly longer event-free survival was not demonstrated with tisagenlecleucel in the second-line setting when compared to standard-of-care second-line therapy in patients with refractory or early relapsed aggressive B-cell lymphoma.

Findings from the GALAHAD clinical trial highlight the importance of molecular testing to inform treatment and disease management decision for prostate cancer.

Ursula A. Matulonis, MD, discusses the impact of PARP inhibitors on ovarian cancer treatment.

The addition of bevacizumab to erlotinib did not demonstrated improvement in overall survival in patients with EGFR-mutant non–small cell lung cancer treated in a phase 3 study.

Fast track designation has been granted to 7HP349, in combination with a CTLA-4 inhibitor for the treatment of patients with unresectable or metastatic malignant melanoma following treatment failure with a PD-1 inhibitor.

A supplemental new drug application seeking FDA approval for darolutamide and docetaxel for the treatment of patient with metastatic hormone-sensitive prostate cancer has been submitted.

Epcoritamab had been granted orphan drug designation by the FDA for the treatment of follicular lymphoma and is being studied in a phase 1/2 clinical trial.

Srdan Verstovsek, MD, discussed the ways in which ropeginterferon and rusfertide can reduce thromboembolic events in polycythemia vera.

In the phase 3 TROPICS-02 clinical trial, sacituzumab govitecan demonstrated a 30% reduction in the risk of disease progression or death versus chemotherapy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer.

The phase 3 NuTide:121 study of acelarin was terminated due to failing to meet a primary end point of overall survival benefit.

Updated data from the ongoing phase 1b/2 trial of batiraxcept in combination with cabozantinib shows favorable outcomes in patients with clear cell renal cell carcinoma.

In the REFINE trial treatment with navitoclax to ruxolitinib in patients with myelofibrosis, spleen reduction has been observed.

A partial clinical hold has been placed the NEON-2 trial by the FDA due to a concern with the safety of davoceticept used in combination with pembrolizumab to treat patients with advanced solid tumors.

Ronald L. Paquette, MD, discusses how transplant related morbidity and mortality risks differ between age groups for patients with myelodysplastic syndrome.

Pembrolizumab given in the adjuvant setting to patients with resected stage IIB and IIC melanoma shows benefit over placebo.

Melissa M. Hardesty, MD, discusses the challenges faced within the community setting in regard to the treatment landscape for advanced ovarian cancer.

The FDA has granted priority review to ivosidenib tablets as a potential treatment for patients with previously untreated IDH1-mutated acute myeloid leukemia.

The NCCN guidelines for myeloproliferative neoplasms now include ropeginterferon alfa-2b, which was recently granted FDA approval for the treatment of polycythemia vera.

Dosing has begun in patients with advanced non–small cell lung cancer in the phase 1/2 Acclaim-1 clinical trial of quaratusugene ozeplasmid in combination with osimertinib after disease progression on osimertinib alone.

In an interview with Targeted Oncology, Tanya Dorff, MD, discussed the exploration of chimeric antigen receptor T-cell therapy in prostate cancer, including recent findings from a phase 1 clinical trial.

In an interview with Targeted Oncology, Ryan Sugarman, MD, discussed the CheckMate 649 trial and Q-TWiST results to provide a further understanding of survival and quality of life benefit of nivolumab plus chemo versus chemo alone.

Yuliya Mikheeva, MD, discusses the phase 2 ANAPLAST-NEO study for patients with anaplastic thyroid cancer.

In an interview with Targeted Oncology, Lori Leslie discussed the CAR T-cell product, brexucabtagene autoleucel, and its influence on both MCL and indolent lymphomas.

Nivolumab in combination with platinum-doublet chemotherapy has been granted FDA approval as neoadjuvant treatment for adult patients with resectable non-small cell lung cancer.